Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease

被引:5
作者
Imran, Saira [1 ]
Golden, Andrew [2 ]
Feinstein, Marc [1 ]
Plodkowski, Andrew [3 ]
Bodd, Francis [2 ]
Rekhtman, Natasha [2 ]
Travis, William D. [2 ]
Stover, Diane E. [1 ]
Sauter, Jennifer L. [2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pulm Med, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA
关键词
acute lung injury; diffuse alveolar damage; immune check-point inhibitor-related pneumonitis; lung histopathology; organising pneumonia; ADVERSE EVENTS; PEMBROLIZUMAB; IMMUNOTHERAPY;
D O I
10.1111/his.14704
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims To improve understanding of the pathology of immune check-point inhibitor (ICI)-related pneumonitis, clinical, radiographic and histopathological features and outcomes were investigated in a cohort of patients who were treatment-naive before receiving ICI inhibition, who underwent lung biopsy, and in whom other potential causes of lung injury were excluded. Methods Patients were retrospectively identified via searches of institutional pathology and clinical records. Patients treated with other modalities for cancer and patients with lung infections or other aetiologies that could cause pneumonitis were excluded. Clinical records were reviewed by pulmonologists. Imaging studies at presentation and follow-up were reviewed by a thoracic radiologist. Pathology was reviewed by thoracic pathologists. Results Six patients with ICI-related pneumonitis were identified. Two patients presented with respiratory failure requiring mechanical ventilation, diffuse ground glass opacities (GGOs) on chest computed tomography (CT) and acute lung injury (ALI) pattern on transbronchial lung biopsies and had fatal outcomes, despite treatment. The remaining four patients presented with less severe symptoms, predominantly consolidations and patchy ground glass and part solid opacities on chest CT, organising pneumonia (OP) or chronic interstitial inflammation histologically, and showed favourable responses to treatment and remission within months. Conclusions This study highlights two radiological-pathological patterns of ICI-related pneumonitis with different behaviour: (1) severe respiratory symptoms and diffuse GGOs on imaging correlating with ALI pattern histologically and poor prognosis; and (2) mild respiratory symptoms and consolidations or patchy subsolid opacities on imaging correlating histologically with OP or chronic interstitial inflammation and good outcomes.
引用
收藏
页码:724 / 731
页数:8
相关论文
共 25 条
  • [1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
    Abdel-Wahab, Noha
    Shah, Mohsin
    Suarez-Almazor, Maria E.
    [J]. PLOS ONE, 2016, 11 (07):
  • [2] Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
    Barjaktarevic, Igor Z.
    Qadir, Nida
    Suri, Anu
    Santamauro, Jean T.
    Stover, Diane
    [J]. CHEST, 2013, 143 (03) : 858 - 861
  • [3] Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance
    Couey, Marcus A.
    Bell, R. Bryan
    Patel, Ashish A.
    Romba, Meghan C.
    Crittenden, Marka R.
    Curti, Brendan D.
    Urba, Walter J.
    Leidner, Rom S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
    Ishiwata, Tsukasa
    Ebata, Takahiro
    Iwasawa, Shunichiro
    Matsushima, Jun
    Ota, Satoshi
    Nakatani, Yukio
    Tsushima, Kenji
    Tada, Yuji
    Tatsumi, Koichiro
    Takiguchi, Yuichi
    [J]. INTERNAL MEDICINE, 2017, 56 (17) : 2311 - 2315
  • [5] Johkoh T, 2021, RADIOLOGY, V298, P550, DOI [10.1148/radiol.2021203427, 10.1016/j.chest.2020.11.027]
  • [6] Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management
    Kalisz, Kevin R.
    Ramaiya, Nikhil H.
    Laukamp, Kai R.
    Gupta, Amit
    [J]. RADIOGRAPHICS, 2019, 39 (07) : 1923 - 1937
  • [7] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
    Khunger, Monica
    Rakshit, Sagar
    Pasupuleti, Vinay
    Hernandez, Adrian V.
    Mazzone, Peter
    Stevenson, James
    Pennell, Nathan A.
    Velcheti, Vamsidhar
    [J]. CHEST, 2017, 152 (02) : 271 - 281
  • [8] Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
    Koelzer, Viktor H.
    Rothschild, Sacha I.
    Zihler, Deborah
    Wicki, Andreas
    Willi, Berenika
    Willi, Niels
    Voegeli, Michele
    Cathomas, Gieri
    Zippelius, Alfred
    Mertz, Kirsten D.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [9] Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma
    Kucukarda, Ahmet
    Gokmen, Ivo
    Ozcan, Erkan
    Peker, Pinar
    Akgul, Fahri
    Cicin, Irfan
    [J]. IMMUNOTHERAPY, 2022, 14 (06) : 395 - 399
  • [10] Kuint R, 2017, RESPIR MED CASE REP, V20, P95, DOI 10.1016/j.rmcr.2017.01.003